After several months of inactivity on the stock transaction front of Harvard Bioscience, Inc. (NASDAQ:HBIO), the specialized product manufacturer’s Chief Financial Officer, Robert E. Gagnon, made his first acquisition of 5,000 shares, directly, paying a price of $3.85 per share. This insider purchase is the first to be completed since the beginning of fiscal 2014, which reported several stock sales on behalf of company Directors Neal Harte and David Green in May and April, but no acquisitions.
However, several hedge funds benefitted from their Harvard Bioscience holdings this past quarter, as evidenced by Chuck Royce’s Royce & Associates, which owns $3.6 million worth of shares (767,100), and Jim Simon’s hedge fund, Renaissance Technologies, with its 584,574 shares worth $2.7 million. Zeke Ashton’s hedge fund, Centaur Capital Partners, added another 10% of the 126.2 million market cap business to its portfolio, and now owns a total of 285,000 shares for a value of $1.3 million.
10 Glaring Plot Holes in The Walking Dead that a Zombie-Filled Bus Could Drive Through
The 5 Biggest Celebrity Stoners Who Love Their Reefer